Trial
NCT01510561
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Metastatic Pancreatic Adenocarcinoma
Intervention
90Y-hPAM4
Why stopped
no subjects enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-19